| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92079c6d95687ee1a7ee1762f27e8d81 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7016 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2016-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f76692513ed398ed45d2db8421d08596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e0d45e65ec267ec7495dbd6d6890ccb |
| publicationDate |
2016-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016243144-A1 |
| titleOfInvention |
Fixed dose combination formulations of rifaximin and lactulose |
| abstract |
A fixed dose combination formulation of rifaximin or a pharmaceutically acceptable salt thereof and lactulose is provided. The formulation is used for the prevention, treatment, or maintaining remission of HE; reducing the recurrence of HE episodes; reducing the recurrence of HE episodes in a patient refractory or non-responsive to rifaximin or lactulose monotherapy; or reducing the frequency of hospital visit. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020360421-A1 |
| priorityDate |
2015-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |